AgendaSaturday, September 14, 2024

6:30 AM - 7:00 AM

Registration and Breakfast

7:00 AM - 7:05 AM

Opening Remarks

by Moderator Alan F. Schatzberg, MD

7:05 AM - 8:05 AM

A Person-Centered Approach to Crisis De-escalation in Patients with Mood Disorders

Presented by Samantha Rabins, LCSW

It's suicide awareness week and we are at a Mood Disorders Summit. Let's talk about a person-centered approach to de-escalation, honing our skillsets in recognizing triggers, implementing strategies to reduce tension and promote safety, determine when additional crisis intervention resources are needed, and construct safety plans for people who are in crisis.

8:05 AM - 8:10 AM

Break

8:10 AM - 9:10 AM

Elevating MDD Care: Integration of Prescription Digital Therapeutics Into MDD Treatment

Presented by David Mohr, PhD

Digital therapeutics can leverage neuroplasticity to address residual symptoms in MDD. This session explores the evolving role of prescription digital mental health therapies in the treatment of MDD, providing practical strategies for prescribing, counseling patients, and integrating them into patient care plans.

9:10 AM - 9:20 AM

Break

9:20 AM - 10:20 AM

Non-CME Educational Session

MDOutlook / Clinical Care Solutions, a CEA Company

Long-Term Strategies in Treatment-Resistant Depression

Sponsored by Johnson & Johnson. Presented by: Rayan Al Jurdi, MD and Karah Brashier, DNP, APRN, MSN, C-PMHNP

“Long-Term Strategies in Treatment-Resistant (TRD) Depression,” an educational program focusing on the continuing care of adult patients with TRD.

  • Review a patient case study to define treatment-resistant depression (TRD)—patients with major depressive disorder (MDD) with an inadequate response to 2 or more oral antidepressants—and review some of their most important concerns
  • Clinical efficacy data in TRD for SPRAVATO® (esketamine) CIII nasal spray
  • 5+-year results from a long-term, open-label safety study of SPRAVATO®
  • Factors to consider when starting patients on SPRAVATO®
  • Important Safety Information

This non-CME educational program is sponsored by Johnson & Johnson.

10:20 AM - 10:30 AM

Wellness Break

10:30 AM - 11:30 AM

Empowering Recovery: Targeted Therapies for Postpartum Depression

Presented by Jennifer Payne, MD

Novel targeted treatment options are now available for postpartum depression. The session will discuss screening and diagnostic strategies, the latest clinical evidence for new and emerging treatment options in PPD, and real-world patient cases.

11:30 AM - 12:30 PM

Addressing the Complexities of Bipolar Depression with DSM Specifiers

Presented by Charles DeBattista, MD

Bipolar depression identification and management can be confusing in the presence of the DSM-V-TR specifiers, including mixed features and anxious distress. This session will seek to clarify best practices for identification and management of bipolar depression with DSM-V-TR specifiers, through interactive case-based discussions.

12:30 PM - 1:00 PM

Break & Lunch

1:00 PM - 2:00 PM

Non-CME Educational Session

MDOutlook / Clinical Care Solutions, a CEA Company

A Clinical Overview of VRAYLAR: Managing the Full Spectrum of Bipolar I Disorder in Adults

Sponsored by AbbVie Pharmaceuticals. Presented by: Rakesh Jain, MD

This presentation provides a clinical overview of VRAYLAR (cariprazine), for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This non-CME educational program is sponsored by AbbVie Pharmaceuticals.

2:00 PM - 2:10 PM

Wellness Break

2:10 PM - 3:10 PM

Clinical Crossroads: Navigating MDD Treatment Challenges Through Real-World Cases

Presented by Greg W. Mattingly, MD

This interactive session will address the complexities of treating Major Depressive Disorder (MDD) through the use of real-world patient cases illustrating common and challenging scenarios in MDD management, focusing on adjunctive therapy strategies. Through these cases, evidence-based adjunctive therapies will be explored, discussing their practical application in clinical settings. This session aims to equip clinicians with the skills and knowledge to navigate the intricacies of MDD treatment, optimize patient outcomes, and personalize care plans.

3:10 PM - 4:10 PM

Unlocking Hope: Psychedelics in the Treatment of Major Depressive Disorder

Presented by Joshua Woolley, MD, PhD

Research into the potential psychiatric utility of psychedelic drugs has been ongoing for decades but has only lately begun to reach mainstream clinical practice. This session will cover current clinical evidence for use of agents such as psyilocybin, MDMA, and ketamine for treatment of major depression, as well as providing resources for clinicians interested in offering psychedelic-assisted therapy for their patients.

4:10 PM - 4:15 PM

Closing Remarks

by Moderator Alan F. Schatzberg, MD